Diversified Healthcare Trust manufactures sterile compounded pharmaceuticals for hospitals and clinics across the US, reporting $1.54B in 2025 revenue but facing persistent net losses.
Despite recent losses, DHC demonstrates robust top-line growth with revenue increasing 20% over the past three years, suggesting strong underlying demand for its sterile compounding services. The company's market leadership position and specialized regulatory compliance create a high barrier to entry that could support margin expansion once operational efficiencies are realized. A turnaround in profitability could unlock significant value given the substantial equity base of $1.67B and total assets of $4.36B.
The company has posted consecutive years of heavy losses, with net income deteriorating from -$15.8M in 2022 to -$370.3M in 2024 before a slight rebound, raising serious concerns about long-term viability. Persistent negative operating cash flow and a massive retained earnings deficit indicate that current operations are burning through capital without generating sustainable returns. Investors should be wary of the heavy depreciation load and the risk that regulatory or market shifts could exacerbate these fundamental financial weaknesses.
Diversified Healthcare Trust (DHC) is a leading provider of sterile compounded pharmaceutical products serving hospitals, clinics, and pharmacies across the United States. The company operates primarily through its compounding division, manufacturing high-quality medications for specific patient needs in both acute care and outpatient settings. With revenue reaching $1.54B in 2025, DHC maintains a significant market presence despite recent challenges in profitability.
Management reported a net loss of $-285.9M for 2025, marking an improvement from the -$370.3M loss in 2024, yet the company continues to operate with negative operating profit and cash flow from operations. While revenue grew steadily from $1.28B in 2022 to $1.54B in 2025, the inability to convert this top-line growth into profitability highlights severe structural cost challenges or one-time impairments not fully detailed in the provided metrics. The company's cash position weakened slightly with a net change of -$28.1M, ending with $121.8M in cash and equivalents after significant financing outflows.
The US compounded pharmaceutical industry is highly regulated and competitive, with strict FDA oversight governing sterile product manufacturing and distribution. Companies in this sector serve a critical niche for patients requiring non-FDA-approved formulations, though they face constant pressure from reimbursement rates and legislative changes. The market is consolidating as larger players acquire smaller compounding facilities to achieve economies of scale and regulatory compliance.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.28B | $1.41B | $1.50B | $1.54B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $1.28B | $1.41B | $1.50B | $1.54B |
| Operating Expenses | $1.30B | $1.68B | $1.87B | $1.86B |
| Operating Income | $-21.1M | $-272.7M | $-371.4M | $-320.9M |
| G&A | $26.4M | $26.1M | $26.5M | $45.5M |
| Stock-Based Comp | $1.7M | $1.8M | $2.7M | $3.4M |
| D&A | $239.3M | $284.1M | $285.0M | $261.9M |
| Depreciation | $239.3M | $284.1M | $285.0M | $261.9M |
| Other OpEx | $1.28B | $1.66B | $1.84B | $1.81B |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $209.4M | $191.8M | — | — |
| Pre-Tax Income | $-21.1M | $-272.7M | $-371.4M | $-320.9M |
| Income Tax | $710.0K | $445.0K | $467.0K | $1.7M |
| Continuing Ops | $-21.8M | $-273.1M | $-371.9M | $-322.6M |
| Discontinued Ops | $6.1M | $-20.5M | $1.6M | $36.8M |
| Net Income | $-15.8M | $-293.6M | $-370.3M | $-285.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-15.8M | $-293.6M | $-370.3M | $-285.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $658.1M | $245.9M | $144.6M | $105.4M |
| Operating Leases | $26.5M | $23.4M | $20.0M | $16.5M |
| Total Assets | $6.00B | $5.45B | $5.14B | $4.36B |
| Total Liabilities | $3.36B | $3.11B | $3.18B | $2.70B |
| Shareholders' Equity | $2.64B | $2.34B | $1.96B | $1.67B |
| Retained Earnings | $2.07B | $1.78B | $1.41B | $1.12B |
| AOCI | — | — | $-17.0K | $-12.0K |
| Total L&E | $6.00B | $5.45B | $5.14B | $4.36B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-15.8M | $-293.6M | $-370.3M | $-285.9M |
| Non-Cash Adjustments | $-20.1M | $333.6M | $501.8M | $219.1M |
| Working Capital Changes | $-4.5M | $-29.5M | $-19.4M | $47.2M |
| Cash from Operations | $-40.4M | $10.5M | $112.2M | $-19.6M |
| Cash from Investing | $387.7M | $-202.1M | $-187.0M | $483.6M |
| Share Buybacks | $171.0K | $393.0K | $904.0K | $1.1M |
| Dividends Paid | $9.6M | $9.6M | $9.6M | $9.7M |
| Cash from Financing | $-676.0M | $-249.7M | $-22.3M | $-492.0M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-328.6M | $-441.3M | $-97.1M | $-28.1M |
| Beginning Cash | $1.02B | $688.3M | $247.0M | $149.9M |
| Ending Cash | $688.3M | $247.0M | $149.9M | $121.8M |
The company's primary revenue stream is derived from its Sterile Compounding business, which generates gross profit of $1.54B against total revenue of the same amount, indicating a service-based model with minimal cost of goods sold relative to traditional manufacturing. A secondary segment involves equity investments in affiliated entities and joint ventures, contributing $36.8M in affiliate profits and $27.2M in specific investments as of the latest reporting period.
The company faces significant financial risk due to a substantial retained earnings deficit of $1.12B and persistent net losses exceeding $300M annually over the last four years. Operational cash flow remains negative at -$19.6M, forcing reliance on financing activities which saw outflows of nearly $500M in the most recent period. Regulatory changes or shifts in reimbursement policies for compounded drugs could further compress margins or reduce demand. High depreciation charges of $261.9M suggest heavy capital intensity and potential obsolescence risks if market dynamics shift.
DHC possesses extensive regulatory expertise and specialized manufacturing capabilities for sterile compounding, allowing it to navigate complex FDA requirements that smaller competitors struggle with. The company benefits from long-term contracts with major hospital systems and pharmacy chains, providing revenue stability despite recent operational headwinds. Its vertically integrated production facilities ensure consistent quality control and supply chain resilience for critical patient medications.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.